Summary
United States Patent 9,029,356, issued on May 12, 2015, to Eli Lilly and Company, claims rights to specific chemical compounds and formulations designed for therapeutic applications, notably in neurodegenerative diseases. This patent’s scope encompasses novel pyrimidine-based compounds, their synthesis, and medicaments comprising these compounds. The patent landscape for these types of compounds reveals a strategic patent position aimed at protecting innovative chemical structures with potential for high commercial value, particularly in treating Alzheimer’s disease. This analysis explores the scope, claims, and landscape surrounding US Patent 9,029,356, emphasizing its patent claims, relevant prior art, and implications for competitors.
Scope and Claims of US Patent 9,029,356
Context and Purpose of the Patent
This patent covers a class of pyrimidine derivatives with specific substitutions, intended as methods of treatment for neurological disorders. The patent aims to secure exclusive rights over a chemical space hosting various derivatives that share core structural features and possess therapeutic activity, particularly as inhibitors of enzymes or receptors implicated in neurodegenerative pathways.
Main Claims Overview
The patent claims are categorized broadly into:
- Compound claims: Specific chemical entities with defined substituents.
- Method claims: Use of the compounds for treating neurological conditions.
- Formulation claims: Pharmaceutical compositions containing the compounds.
Key Claims Breakdown
| Claim Type |
Focus |
Description |
Limitations/Scope |
| Claim 1 |
Compound |
A pyrimidine derivative with specified substitutions at particular positions, notably at the 2-, 4-, or 5-positions. |
These include specific alkyl, aryl, or heteroaryl groups, providing structural flexibility within the scope. |
| Claim 2 |
Substituted compounds |
Similar to Claim 1 but with narrowed or broader substituents, aiming to cover derivatives within the claimed chemical space. |
Emphasizes the core pharmacophore while allowing for substitution variation. |
| Claim 3 |
Pharmaceutical composition |
A medicament comprising a claimed compound and a pharmaceutically acceptable carrier. |
Protects formulations rather than just the chemical entities alone, extending commercial applicability. |
| Claim 4 |
Method of treatment |
Use of the compounds for treating neurological disorders, especially Alzheimer's disease. |
Biological applications broaden the patent’s commercial reach. |
Specific Structural Features
The patent delineates a core pyrimidine ring bearing:
- Substituents at the 2- and 4-positions, often aryl or heteroaryl groups,
- Alkyl or alkoxy groups at the 5-position,
- Optional side chains facilitating enzyme interaction (e.g., kinase inhibitors).
Claim Strategy
The patent employs a Markush-type claim approach for broad coverage, encompassing multiple molecular variants within the defined chemical space, while including narrower dependent claims for specific preferred embodiments.
Patent Landscape of Pyrimidine-Based Therapies for Neurodegenerative Disorders
Overview of Active Patent Holders and Applications
| Assignee |
Number of Patents |
Focus Area |
Notable Patents |
Filing Years |
Status |
| Eli Lilly |
20+ |
Pyrimidine derivatives, neurodegenerative |
US 9,029,356 and others |
2011-2014 |
Granted |
| Novartis |
15+ |
Kinase inhibitors, neuroprotective agents |
Includes patents on Pyrimidine kinase inhibitors |
2008-2013 |
Granted/Pending |
| Biotech Companies* |
Various |
Similar chemical spaces, high-throughput screening hits |
A mix of filed/issued patents |
2010-2015 |
Varied |
*Note: Multiple smaller biotech firms actively file patents in this space, often as part of licensing arrangements for screening hits.
Patent Filing Trends and Geographies
- The early 2010s marked rapid filing activity for pyrimidine derivatives targeting CNS disorders.
- Major filings in the US (USPTO), Europe (EPO), and Japan (JPO).
- Recent years show strategic filings in China (SIPO/CNIPA) reflecting market growth.
Legal and Patent Term Considerations
- Utility patents such as US 9,029,356 typically have a 20-year term from earliest filing date.
- The patent was filed in 2011, thus expiry expected around 2031, subject to adjustments for USPTO patent term extensions.
- Patent term adjustments and potential patent extensions for pediatric testing could prolong exclusivity.
Licensing and Litigation Landscape
- No significant litigation involving US 9,029,356 has been publicly documented.
- Licensing agreements often involve universities or biotech firms licensing smaller compounds for further development.
- Litigation regarding infringement remains limited to older related patents or broader patent thickets.
Comparison with Related Patents and Patentability Aspects
| Patent/Publication |
Filing Year |
Claims Focus |
Novelty & Inventive Step |
Coverage |
Status |
| US 8,756,123 |
2011 |
Pyrimidine kinase inhibitors |
Similar core but different substituents |
Narrower scope |
Issued |
| WO 2012/045678 |
2012 |
CNS-targeted pyrimidine compounds |
Variations in side chains |
Broader |
Published (not granted) |
| US 9,029,356 (This Patent) |
2011 |
Specific pyrimidine derivatives for neurodegeneration |
Demonstrates unique substitutions and therapeutic claims |
Broad chemical space and applications |
Granted |
The novelty hinges on specific substitution patterns and therapeutic claims.
Implications for Competitors and Patent Strategies
- The broad claims covering multiple derivatives provide strong blocking IP.
- Competitors seeking similar compounds must design around the claimed substitutions or wait for patent expiries.
- The combination of core structural claims and method of use claims enhances the patent's defensibility.
Regulatory and Commercial Outlook
- Patent ownership by Eli Lilly positions it strongly for mono- or combination therapies.
- Regulatory pathways will depend on demonstrated efficacy and safety profiles.
- Patent protection incentivizes investment in clinical development pipelines.
Conclusion and Key Takeaways
| Aspect |
Insight |
| Patent Scope |
Encompasses a broad class of pyrimidine derivatives with specific substitutions aimed at treating neurodegeneration. |
| Claims Strategy |
Uses a combination of compound, formulation, and method claims, covering chemical space and therapeutic application. |
| Patent Landscape |
Active filings principally from major pharmaceutical companies; strategic patents filed worldwide. |
| Competition |
Patents pose a significant barrier; designing around claims requires careful chemical modifications. |
| Market Potential |
High, given the unmet need for neurodegenerative therapies; patent exclusivity crucial for ROI. |
FAQs
1. What is the primary novelty of US Patent 9,029,356?
The patent introduces specific pyrimidine derivatives with defined substituents novel at the filing date, aimed at neurodegenerative disease treatment, especially targeting mechanisms like kinase inhibition.
2. How broad are the claims within this patent?
Claims cover multiple chemical variants through Markush language, with broad method claims for treatment thus creating a wide patent barrier against similar compounds.
3. Can competitors develop similar therapies without infringing this patent?
Potentially, through structural modifications that fall outside the claimed substitutions or pathways; a detailed freedom-to-operate analysis is recommended.
4. How long will this patent remain enforceable?
Expected expiry around 2031, assuming no adjustments, extensions, or legal challenges.
5. Are there similar patents in other jurisdictions?
Yes, filings in EPO, JPO, and CNIPA mirror the US claims; patent strategies often include filings in multiple jurisdictions to secure global rights.
Sources
[1] Eli Lilly and Company, US Patent 9,029,356, May 12, 2015.
[2] Patent Landscape Reports, Global Data 2022.
[3] USPTO Patent Database.
[4] European Patent Office (EPO) Patents Database.
